Comparative Pharmacology
Head-to-head clinical analysis: LAMISIL versus MONISTAT 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMISIL versus MONISTAT 3.
LAMISIL vs MONISTAT 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allylamine antifungal that inhibits squalene epoxidase, an enzyme in the ergosterol biosynthesis pathway, leading to accumulation of squalene and disruption of fungal cell membrane function.
Miconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
250 mg orally once daily for 2-6 weeks for dermatophyte infections; 250 mg orally once daily for 12 weeks for onychomycosis.
One vaginal suppository (200 mg miconazole nitrate) intravaginally at bedtime for 3 consecutive days; or one applicatorful (5 g) of 4% vaginal cream intravaginally at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 17-24 hours in healthy adults. However, it can prolong to about 36-40 hours in patients with renal or hepatic impairment. The prolonged half-life allows for once-daily dosing. Due to extensive tissue distribution, the functional half-life (terminal phase from tissues) may be longer.
Terminal elimination half-life is approximately 30 hours after topical vaginal application; prolonged in hepatic impairment.
Approximately 70% of the administered dose is excreted in the urine as metabolites, with less than 5% as unchanged drug. About 20% is eliminated via feces. Terbinafine undergoes extensive hepatic metabolism; renal elimination of metabolites is the primary route.
Primarily fecal (97%) via biliary excretion; renal excretion of unchanged drug is negligible (<1%).
Category C
Category C
Antifungal
Antifungal